The Elton John AIDS Foundation is in the top 5 philanthropic funders of HIV/AIDS grants worldwide. Since our founding, we have raised over $660 million to support over 3,236 projects in 108 countries to end AIDS. In 2025, our U.S. And u.k. Entities together reached 523,000 people with HIV services and funded $18,768,059 of new grants. The U.S. Entity alone awarded $11,717,713 of grants and spent $… Read more
The Elton John AIDS Foundation is in the top 5 philanthropic funders of HIV/AIDS grants worldwide. Since our founding, we have raised over $660 million to support over 3,236 projects in 108 countries to end AIDS. In 2025, our U.S. And u.k. Entities together reached 523,000 people with HIV services and funded $18,768,059 of new grants. The U.S. Entity alone awarded $11,717,713 of grants and spent $16,479,482 on program services, 85% of our total expenses. See schedule o for continuation.Elton John AIDS Foundation inc. Was founded by elton john in 1992 and is governed by a board of philanthropic leaders, technical experts, corporate executives and leaders in the global HIV/AIDS response. In 2020, we embarked on an exciting strategic plan, designed to reduce stigma and HIV transmission, ensure that everyone has access to compassionate care and treatment, and that governments invest equitably in those populations most affected by HIV. Our strategy focuses on reaching the most marginalized populations and communities that are so often left behind and excluded from the HIV response.the Elton John AIDS Foundation's grantmaking is made from both its U.S. Entity (to which this form 990 relates) and u.k. Entity. As reported in the foundation's annual report, available on our website, the foundation awarded 44 new grants to the value of $18,768,059 in 2025, of which $11,717,713 was from the U.S. Entity alone. We reached 523,000 people with services including testing, prevention, treatment, training and education, with grants spanning 68 countries. We initiated 26,857 people on pre-exposure prophylaxis (prep), initiated 20,984 on antiretroviral therapy (art) and supported 230,692 people to test for HIV. Grants were awarded across our strategic portfolio areas:1. Young people: To meet the growing global health needs of young people and prevent a resurgence of the HIV/AIDS epidemic, we are supporting our partners to pilot and scale effective public health responses which meet young people where they are through innovations in service delivery. 2. LGBTQ+: LGBTQ+ groups are at increased risk of HIV infection. We are working to ensure LGBTQ+ people have access to protection and appropriate, quality health care.3. United states of America: The HIV/AIDS epidemic in the united states will not end without concerted action from both the public and private sector. We are strengthening these partnerships to enhance health workforce capabilities, to increase the accessibility and demand for HIV prevention and testing commodities, to enhance linkages to care within communities, and to address national, state, and local policy barriers for people living with HIV and those at heightened risk of infection.4. Eastern europe and central asia: In eastern europe and central asia, HIV infections and aids-related deaths continue to rise, demanding urgent action to turn the tide of the epidemic. To achieve epidemic control in eeca, we are working to improve and expand HIV services for all, to reduce stigma and discrimination experienced by key populations, and to share learning on effective approaches. In response to the outbreak of war in ukraine and increased burdens on the health system, we are making strategic investments to bolster and sustain the HIV/AIDS response during this crisis. 5. People who use drugs: We are working to ensure people who use drugs have access to relevant and effective treatment strategies, and can rely on continued investment to meet their health needs.our current strategic plan will conclude in 2026 and we will use the year to focus on closing out our existing programs strongly and evaluating the successes and learnings from the projects we have funded over the past five years. These insights will inform the new strategy, which is currently being developed with deep engagement from both the board and management and will be implemented from 2027 onward.financial review:the foundation consists of a u.k. Entity and a U.S. Subsidiary entity (to which this form 990 relates), in combination referred to as the "group". The directors manage the grant making, fundraising, and other operations of the organisation jointly across the group. As reported in the annual report available on our website, total combined revenue for the group in 2025 was $25,673,153 (2024: $29,718,676), Thanks to the ongoing success of the rocket fund, our multi-year fundraising initiative designed to accelerate the foundation's life-saving work. This included $21,226,655 of revenue generated in the U.S. Entity alone (2024: $20,298,674). During the year, we announced the expansion of the rocket fund to $200 million, to ensure we can meet rising needs and continue driving impact worldwide. In a year marked by severe funding cuts across global health programs, the foundation remained unwavering in its commitment to the communities most at risk. As reported in the annual report, the group invested $25,796,536 in expenditure on charitable activities in 2025 (2024: $27,885,498) Whilst the U.S. Entity alone spent $16,479,482 on program services (2024: $17,528,743), Representing 85% of total expenses in the entity (2024: 88%). As reported in the annual report, the group recorded a deficit of $6,003,525 (2024: $3,790,670), Resulting in net assets of $23,993,190 at December 31, 2025 ($29,996,715 at December 31, 2024). This reflected our intentional decision to draw on excess reserves built from surpluses in earlier years of the current strategic plan, enabling us to maximize our impact during a challenging period for the sector. At a time when many were scaling back, it was essential that we maintained, and in some cases extended, funding for our partners facing cuts from elsewhere.as reported in this form 990, the U.S. Entity recorded a surplus of $1,781,370 (2024: $303,061), Which together with unrealized gains on investments and other changes in net assets, resulted in net assets of $17,966,810 at December 31, 2025 ($16,050,177 at December 31, 2024). At the end of 2025, the group and U.S. Entity continue to hold robust reserves, ensuring operational stability and positioning us strongly to deliver on our strategy.